fbpx

UIC Scientific Advisory Council

Scientists, political lobbyists and lawyers helping UIC in delivering up to date information and news.
Justin Sinclair
UIC Chief Scientist, Pharmacognosist & Educator

Justin is a Pharmacognosist & Educator, and has spent decades exploring the diverse field of herbal medicine, both from a scientific ando…

More

Justin Sinclair

Justin is a Research Fellow at the NICM Health Research Institute, an international leader in integrative medicine research based at Western Sydney University. He is also the co-ordinator of the Australian Medicinal Cannabis Research & Education Collaboration (AMCREC) and has also served on United in Compassion’s Scientific Advisory Board, Australia’s leading medicinal cannabis patient advocacy group, in a pro bono capacity since January 2015.

His scientific background is in pharmacognosy (i.e. drugs that come from plants, fungi and natural sources), but his research interests extend into botany, ethnopharmacology, analytical phytochemistry and psychopharmacology. He is currently a co-investigator on several medicinal cannabis clinical research projects and has presented over 70 medicinal cannabis lectures to medical practitioners, nurses, pharmacists and the general public since 2016. Justin has published on the topics of cannabis and the endocannabinoid system, pain management and herb/drug interactions in peer reviewed publications and is a member of the Society of Cannabis Clinicians and International Cannabinoid Research Society.

Disclosures
1. Research Fellow, NICM Health Research Institute (NICM) at Western Sydney University.
2.Co-ordinator, Australian Medicinal Cannabis Research & Education Collaboration (AMCREC)
3. Chief Scientist, Scientific Advisory Board of United in Compassion
4. Former Scientific Advisory Board member, BioCeuticals (Resigned April 2019)
5. Lecturer, Endeavour College of Natural Health.

Bonni Goldstein
Owner & Medical Director, Canna-Centers

Bonni Goldstein, M.D., is the owner and medical director of Canna-Centers, a medical practice devoted to educating patients about the use of…

More

Dr Bonni Goldstein MD

Bonni Goldstein, M.D., is the owner and medical director of Canna-Centers, a medical practice devoted to educating patients about the use of Cannabis for serious and chronic medical conditions. She is also medical advisor to Weedmaps.com, the first and largest global technology and media company in the Cannabis space.

In 2008, Dr. Goldstein developed an interest in the science of medical Cannabis after witnessing its beneficial effects in an ill friend. She has helped thousands of adults and children with chronic and serious medical conditions achieve a better quality of life with the use of Cannabis treatment.

Dr. Goldstein received her undergraduate education at Rutgers College, and earned her medical degree at Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey. She completed both her internship and residency, serving as chief resident, at Children’s Hospital Los Angeles.

Dr. Goldstein was a Clinical Instructor in Pediatrics at USC School of Medicine in Los Angeles, Emergency Transport Attending Physician at Childrens Hospital Los Angeles, and Emergency Medicine Attending Physician in the Pediatric Emergency Department at Los Angeles County-USC Medical Center.

Dr. Goldstein has given numerous lectures to patient support programs, including the Cancer Support Community, Southern California Prosthetics, and Pediatric Epilepsy groups, as well as Cannabis industry events such as Patients Out of Time, CannMed 2016, Women Grow and the Emerald Cup. 

Dr. Goldstein is on the Scientific Advisory Board of United in Compassion, a non-profit group in Australia devoted to educating physicians, politicians and patients about the benefits of Cannabis medicine and on the Scientific Advisory Board for United Patients Group, a non-profit group that educates patients and helps them navigate the ever-changing cannabis industry.

Dr. Goldstein is a member of the Society of Cannabis CliniciansInternational Association of Cannabinoid Medicines, and the International Cannabinoid Research Society.

Dr Bonni Goldstein MD

Canna-Centres

Ilan Linder
Paediatric Neurologist

Dr Linder is a Paediatric Neurologist at the Wolfson Medical Centre in Israel. Ilan has treated over 130 pediatric patients…

More

Iian Linder

Dr Linder is a Paediatric Neurologist at the Wolfson Medical Centre in Israel.

Ilan has treated over 130 pediatric patients with intractable epilepsy over the past two years, including with vaporized Cannabis.

Ilan studied Medicine in Ben-Gurion University in Beer-Sheba, graduating in 1998. His post-doctoral education included Residency and Internship in pediatrics and later in Pediatric neurology & child development at the Edith Wolfson Medical Centre in Holon, Israel, at Professor Tally Lerman-Sagie’s Pediatric Neurology Unit.

Currently Ilan head’s up the Pediatric Epilepsy clinic. His hospital work consists of consultations and specialised clinics, such as catastrophic epilepsies and the metabolic genetic neurologic clinic. Ilan teachs and supervises medical students and pediatric interns and medical nurses in the field of epilepsy. He also practices pediatrics and pediatric neurology in the community.

Ilan first encountered the field of Medical Cannabis during a multi-center trial treating pediatric epileptic patients with Cannabinoid oil extracts and vaporized cannabis. Ilan lead the center’s branch.

Ilan recently spoke at the ‘Israeli League Against Epilepsy’ annual meeting (January 2016), sharing his experience in treating pediatric epileptic patients with vaporized Cannabis. Ilan is a member of the pediatric neurologists committee in the Israeli Ministry of Health, structuring guidelines for the use of Medical Cannabis in pediatric epileptic patients with oil extract and vaporized Cannabis.

Alice O’Leary-Randall
Senior Medical Cannabis Spokesperson

Alice is a senior spokesperson for the Medicinal Cannabis movement. In 1976 her late husband, Robert C. Randall, became the first…

More

Alice O'Leary-Randall

Alice is a senior spokesperson for the Medicinal Cannabis movement.

In 1976 her late husband, Robert C. Randall, became the first person in the U.S. to legally receive Medicinal Cannabis.

The couple went on to co-found the Medical Cannabis movement in America, assisting patients and educating the American public about the therapeutic potential of Cannabis. In 1980 they co-founded Alliance for Cannabis Therapeutics, the nation’s first non-profit organization devoted to Medical Cannabis issues.

They worked side-by-side on the issue until Robert’s death in 2001. At that point Alice embarked on a nursing career to fulfill her desire to work in hospice. She was a hospice nurse for six years, retiring in 2012. She has returned to the Medical Cannabis movement and continues to educate and celebrate the contributions of many brave individuals who courageously fought for medical access to Cannabis. She is the author of Medical Marijuana in America: Memoir of a Pioneer and a frequent contributor to Huffington Post and Cannabis Now Magazine. www.medicalmarijuanapioneer.com

Jeffrey Hergenrather
General Practitioner, Cannabis/Cannabinoid Medicine Specialist

Jeffrey Hergenrather, MD is a general practitioner specializing in cannabis / cannabinoid medicine since 1999…

More

Dr Jeffrey Hergenrather MD

Dr. Jeffrey Hergenrather is a general practitioner specializing in Cannabis/Cannabinoid medicine since 1999.  

His medial experience includes 26 years in emergency medicine and private general practice that includes the medical use of Cannabis since 1977.  He continues in an active consultation practice in northern California with face-to-face, telephone, and on-line consultations for the use of Cannabis as medicine.

Dr. Hergenrather’s practice, research, and teaching focus on the medicinal uses of Cannabis through a wide range of conditions and age groups – from infants to elder care.  He is a founding member and current president of the Society of Cannabis Clinicians, a non-profit corporation dedicated to quality patient care, educational programs, and clinical studies.  

He is a member of the International Cannabinoid Research Society (ICRS) and the International Association for Cannabinoids in Medicine (IACM).  

Additionally, Dr. Hergenrather works as an expert witness and consultant to local governments in industry in creating safe access to Cannabis medicines.

Simon Eckermann
Senior Professor of Health Economics, Australian Health Services Research Institute

Simon Eckermann is Senior Professor of Health Economics at the Australian Health Services Research Institute, Sydney Business School and the University…

More

Professor Simon Eckermann Health Economics

Simon Eckermann is Senior Professor of Health Economics at the Australian Health Services Research Institute, Sydney Business School and the University of Wollongong. He was previously Health Economics Professor at the Flinders University Centre for Clinical Change and Health Care Research and Senior Health Economist at the NHMRC Clinical Trial Centre. He  is a CI on competitive research grants totalling more than A$25 million since 2005 and actively sits on and undertakes guideline revision and health economics educational activities for National decision bodies including the Pharmaceutical Benefits Advisory Committee Economic Sub-Committee (PBAC ESC 2005-2010), National Palliative Care Trials Scientific Committee (2006-2014), Prostheses List Advisory Committee (2012-2014), Victorian Cancer Agency (2015-) and Food Standards ANZ (2017-) as well as various NHMRC grant review committees.

His original research and collaborations have established missing links between optimal decision making in research, reimbursement and regulation in practice and are extensively published in the highest impact health economics and decision making Journals, and clinical and policy journals with his applied research.

Related principles and methods have been taught by Professor Eckermann to more than 500 students from a wide range of clinical, research, policy and health technology assessment backgrounds since 2000, with the ‘Health Economics from Theory to Practice’ course he established with Professor Willan in 2005 consistently rated by participants as the best course of its type internationally.  The Health Economics from theory to Practice text (Eckermann 2017) is recently published by Springer view here and critically for medicinal cannabis policy making addresses the US National Academy of Science call for public health and health economic research. Specifically section 12.5 provides the most comprehensive public health policy evidence synthesis and health economic analysis for optimising Medicinal Cannabis health, economic and environmental impacts in cultivation and provision of medicinal cannabis with precision medicine for optimising net benefit in palliative populations of pain management, the most prevalent indication.  Importantly this highlights the need for good agricultural and manufacturing practice for outdoor and greenhouse cultivated terpene, CBD and THC rich varieties to enable palliative physician optimisation of symptom outcomes but also in meeting key palliative domains for finalising affairs, being in their location community of choice (usually at home) and is within the broader context of chapter 12 policies for optimising budget constrained successful ageing of baby boomer populations. 

More generally methods developed by Professor Eckermann of relevance to health economic analysis of public health questions brought together in the Health Economics from Theory to Practice text, include robust methods for: evidence synthesis and translation (Eckermann, Coory and Willan 2009, 2011); comparison of multiple strategies (Eckermann, Briggs and Willan 2008; Eckermann and Willan 2011); evaluation of health promotion and prevention programs allowing for network multiplier effects (Eckermann et al 2014); evaluating health care efficiency and providers in practice allowing consistent with maximising net benefit in allowing for quality of care (Eckermann and Coelli 2013; Eckermann 2004); multiple domain comparisons, particularly critical to evaluation of areas such as palliative care (McCaffrey et al 2015); optimal research design allowing for relevant policy contexts (Eckermann, Karnon and Willan 2010; Eckermann and Willan 2008, 2009, 2011, 2013; Willan and Eckermann 2010, 2012); optimal adoption, pricing and financing of new technology consistent with the health shadow price (Pekarsky 2012, 2014, Eckermann and Pekarsky 2014) and; optimising current Australian policy reform processes (Eckermann 2014; Eckerman and Sheridan 2016; Eckermann, Sheridan and Ivers 2016).

 

Recent publications:


Agar M, Lawlor P, Quinn S, Draper B, Caplan BA, Rowett D, Sanderson C, Hardy J, Le B,  Eckermann S, McCaffrey N, Devillee L, Fazekas B, Hill M, Currow DC.  2017. Efficacy of oral Risperidone, Haloperidol or Placebo for symptoms of delirium among patients in palliative care: a randomised trial.  JAMA Intern Med. 2017 Jan 1;177(1):34-42. doi: 10.1001/jamainternmed.2016.749. First Published online December 5, 2016. 

 

Eckermann S.  Health Economics from Theory to Practice: Optimally Informing Joint Decisions of Research, Reimbursement and Regulation with Health System Budget Constraints and Community Objectives. Cham, Switzerland. Springer. 2017. DOI 10.1007/978-3-319-50613-5. http://www.springer.com/gp/book/9783319506111

 

Eckermann S.  Policy Implications and Applications Across Health and Aged Care Reform with Baby Boomer Ageing – from Age and Dementia Friendly Communities to Palliative Care.  Chapter 12 in: Health Economics from Theory to Practice: Optimally Informing Joint Decisions of Research, Reimbursement and Regulation with Health System Budget Constraints and Community Objectives. Cham, Switzerland. Springer. 2017. DOI 10.1007/978-3-319-50613-5.

 

Eckermann S.  The Health Shadow Price and Economically Meaningful Threshold Values.  Chapter 11 in: Health Economics from Theory to Practice: Optimally Informing Joint Decisions of Research, Reimbursement and Regulation with Health System Budget Constraints and Community Objectives. Cham, Switzerland. Springer. 2017. DOI 10.1007/978-3-319-50613-5.

 

McCaffrey N , Eckermann S.  Multiple Effects Cost Effectiveness Analysis in Cost-Disutility Space.  Chapter 10 in: Health Economics from Theory to Practice: Optimally Informing Joint Decisions of Research, Reimbursement and Regulation with Health System Budget Constraints and Community Objectives. Cham, Switzerland. Springer. 2017. DOI 10.1007/978-3-319-50613-5.

 

Eckermann S.  Including Quality in Efficiency Measures: Creating Incentives Consistent with Maximising Net Benefit in Practice.  Chapter 9 in: Health Economics from Theory to Practice: Optimally Informing Joint Decisions of Research, Reimbursement and Regulation with Health System Budget Constraints and Community Objectives. Cham, Switzerland. Springer. 2017. DOI 10.1007/978-3-319-50613-5.

 

Eckermann S.  Best Informing Multiple Strategy Cost Effectiveness Analysis and Decision Making: The Cost-Disutility Plane and Expected Net Loss Curves and Frontiers .  Chapter 8 in: Health Economics from Theory to Practice: Optimally Informing Joint Decisions of Research, Reimbursement and Regulation with Health System Budget Constraints and Community Objectives. Cham, Switzerland. Springer. 2017. DOI 10.1007/978-3-319-50613-5.

 

Eckermann S.   Value of Information, Pricing under Uncertainty and Risk Sharing with Optimal Global Trial Design.  Chapter 7 in: Health Economics from Theory to Practice: Optimally Informing Joint Decisions of Research, Reimbursement and Regulation with Health System Budget Constraints and Community Objectives. Cham, Switzerland. Springer. 2017. DOI 10.1007/978-3-319-50613-5.

 

Eckermann S.  Globally Optimal Societal Decision Maker Trials.  Chapter 6 in: Health Economics from Theory to Practice: Optimally Informing Joint Decisions of Research, Reimbursement and Regulation with Health System Budget Constraints and Community Objectives. Cham, Switzerland. Springer. 2017. DOI 10.1007/978-3-319-50613-5.

 

Eckermann S.  The Value of Value of Information Methods to Decision Making: what VOI Measures enable Optimising Joint Research and Reimbursement Decisions Within a Jurisdiction.  Chapter 5 in: Health Economics from Theory to Practice: Optimally Informing Joint Decisions of Research, Reimbursement and Regulation with Health System Budget Constraints and Community Objectives. Cham, Switzerland. Springer. 2017. DOI 10.1007/978-3-319-50613-5.

 

Eckermann S, McCaffrey N.  Beyond the Individual: Evaluating Community-Based Health Promotion and Prevention Strategies and Palliative Care.  Chapter 4 in: Health Economics from Theory to Practice: Optimally Informing Joint Decisions of Research, Reimbursement and Regulation with Health System Budget Constraints and Community Objectives. Cham, Switzerland. Springer. 2017. DOI 10.1007/978-3-319-50613-5.

 

Eckermann S.  Avoiding Frankenstein Monster and Partial Analysis problems: Robustly Synthesising, Translating and Extrapolating Evidence.  Chapter 3 in: Health Economics from Theory to Practice: Optimally Informing Joint Decisions of Research, Reimbursement and Regulation with Health System Budget Constraints and Community Objectives. Cham, Switzerland. Springer. 2017. DOI 10.1007/978-3-319-50613-5.


Eckermann S.  Principles and Practice for Trial Based Health Economic Analysis.  Chapter 2 in: Health Economics from Theory to Practice: Optimally Informing Joint Decisions of Research, Reimbursement and Regulation with Health System Budget Constraints and Community Objectives. Cham, Switzerland. Springer. 2017. DOI 10.1007/978-3-319-50613-5.

David Caldicott
Adjunct Associate Professor, University of Canberra, Emergency Health Consultant

David has worked as a specialist emergency physician for 25 years, is a senior university…

More

Dr David Caldicott MD Adjunct Associate Professor, University Of Canberra

David has worked as a specialist emergency physician for 25 years, is a senior university lecturer and adjunct associate professor.

A founding member of the Australian Medical Cannabis Observatory; the AMCO was created to establish the infrastructure and support systems that an industry will require.

Author of numerous publications, a researcher, educator, with specialties in Novel Illicit Compounds in the ED, Simulation, Medical Education, Innovation in the Emergency Department, Medical Response to Terrorism, Disaster Medicine

Dr David Caldicott MD

Emergency Specialist Doctor

Sue Sisley
Physician, Internal Medicine & Psychiatry Specialist

Dr. Sue Sisley MD is an Arizona-based physician practising Internal Medicine and Psychiatry. She works…

More

Dr. Sue Sisely MD Physician Practising Internal Medicine & Psychiatry

Dr. Sue Sisley MD is an Arizona-based physician practising Internal Medicine and Psychiatry.

She works as Medical Director for medical cannabis license holders in 11 different states/territories from Hawaii to Puerto Rico to New York.

Sue serves as Site Principal Investigator for the only FDA-approved randomized controlled trial in the world examining safety/efficacy of whole plant marijuana in combat veterans with treatment-resistant post traumatic stress disorder PTSD.  Dr. Sisley is on faculty at Colorado State University PUEBLO campus, recruited for core planning team to organize the CSUP “ICR Institute of Cannabis Research” in Pueblo, Colorado. 

Dr. Sisley has been a Member of Nevada ILAC Medical Cannabis Commission for the past two years outlining regulations for laboratory testing including limits on pesticides, residual solvents and other guidelines that are currently being used as a model for other states medical cannabis laws. She also serves on the Steering Committee for Thomas Jefferson University Lambert Cannabis Medical Research Center.